학술논문
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Document Type
Article
Author
Pal, Sumanta Kumar; Albiges, Laurence; Tomczak, Piotr; Suárez, Cristina; Voss, Martin H; de Velasco, Guillermo; Chahoud, Jad; Mochalova, Anastasia; Procopio, Giuseppe; Mahammedi, Hakim; Zengerling, Friedemann; Kim, Chan; Osawa, Takahiro; Angel, Martín; Gupta, Suyasha; Khan, Omara; Bergthold, Guillaume; Liu, Bo; Kalaitzidou, Melania; Huseni, Mahrukh; Scheffold, Christian; Powles, Thomas; Choueiri, Toni K
Source
In The Lancet 15-21 July 2023 402(10397):185-195
Subject
Language
ISSN
0140-6736